Description
Globally, a rising number of people are diagnosed with interstitial lung disease (ILD) and lung cancer each year. Of particular significance is the number of people suffering from these diseases without a diagnosis, resulting in a decreased quality of life and prognosis. This program aims to help clinicians effectively recognize subtle but important warning signs of ILD and lung cancer, conduct appropriate initial investigations, and refer patients promptly to pulmonology/respirology and/or thoracic surgery. The overall goal is to support clinicians to reduce diagnostic delays and improve outcomes.
After completing the CME, explore the accompanying microlearning series (See below the relative links), which reinforces key insights by highlighting persistent cough as an early signal of ILD and lung cancer.
For Physicians microlearning series, click here.
For Pharmacists microlearning series, click here.
This program has received an unrestricted educational grant or in-kind support from Boehringer Ingelheim.